Roche: FDA Grants Priority Review To Gazyva/Gazyvaro For Primary Membranous Nephropathy
* Priority Review Based On Phase III MAJESTY Results Showing Superiority Over Tacrolimus * Phase III MAJESTY: Complete Remission At Two Years Was 36.9% With Gazyva/Gazyvaro Vs. 5.7% With Tacrolimus * MAJESTY Study Data Submitted To Global Health Authorities, Including The European Medicines Agency * If Approved, Gazyva/Gazyvaro Would Be The First FDA-Approved Therapy For Primary Membranous Nephropathy
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.